Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-PRIME: Enfortumab Vedotin and Pembrolizumab with Radiotherapy in Muscle Invasive Bladder Cancer
NCT06470282Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in muscle-invasive bladder cancer (MIBC), sponsored by University of California, San Francisco. Started Mar 2025; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06470282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470282.